Immune Pharma United States

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.

The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.

The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Boris Shor
Executive Director 

Indigo therapeutics France

Indigo therapeutics & Gynov
  • Indigo designs, manufactures and supplies innovative dietary supplements focused on gastrointestinal tract (GIT) pathologies and conditions or deficiencies requiring specific clinical nutrition
  • Gynov, Indigo's sister company, applies the same rules of design and manufacturing for gynecological / obstetrics sphere
Therapeutics Area
  • Gastroenterology / Hepatology
  • Immunology
  • Infectious Diseases - Vaccines
  • Nutrition and Weight Loss
  • Obstetrics/Gynecology (Women's Health)
Our innovative solutions

Besides opportunistic developments, our R&D aims at producing new generation probiotics / synbiotics combining a selection of relevant strains in relation to the progresses on microbiota, a microencapsulation technology promoting the survival and the production of molecules of interest, and a pharmaceutical macro-encapsulation vectorizing active ingredients to the therapeutic target

Problems we address

Indigo addresses medical problems or conditions which currently lack of efficient or well-tolerated solutions. Besides, Indigo provides a clear rational while exploiting the potential of probiotics / synbiotics still faces some uncertainty among healthcare professionals.

Gynov addresses obstetrical issues for which currently available medications are contra-indicated. Thus, Gynov conceives specialized dietary supplements based upon high-quality GRAS ingredients that have demonstrated their efficacy for Gyn/Obst issues

Target market segments
  • Irritable bowel disease (IBD)
  • Prevention & treatment of diarrheas
  • Dialysis for end-stage renal failure
  • Fertility & obstetrics
Key values
  • Robust medico-scientific background
  • High manufacturing & product quality (GMP)
  • Exclusive promotion towards medical doctors
  • High value academic partnerships
Pierre-Yves MOUSSET
CEO 

Inferential France

Inferential  Biostatistical expertise and services for all types of studies Industry sectors Other: Biostatistics Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution

Inferential provides statistical expertise and delivers results and statistical reports for any type of study incl clinical, NIS, health-economics, epidemiology

Which problem are you solving ?

While health authorities are more and more demanding in terms of data quality and study standards, most pharmaceutical companies own less and less skilled statistical resources. Inferential acts as the client's own statistical department or an extension thereof.

Target market segments

1)Pharmaceutical companies 2)Biotechs 3) Device 4) Cosmetics and nutrition 5) Vet

Key value proposition

1) Hign expertise with low overhead costs 2) Broad experience in both US and EMEA regulatory context

Anne HUMMLER
CEO 

Infusion Pharma United States

Infusion Pharma Consulting LLC

Infusion Pharma Consulting specializes in the orphan drug, hospital therapeutics and specialty biopharma markets.  Our key capabilities include strategic pricing and market access, business development, and brand strategy, supported by specialty markets research.  

We are leaders in the orphan drug and rare disease market and serve clients on four continents and in 12 countries.  Our clients range from start-ups to Top 5 companies.          

We look forward to discussing your needs.   

Mr John Maddox
Managing Director 

INPI United States

L'INPI est un établissement public, entièrement autofinancé, placé sous la tutelle du ministère de l'Économie, de l'Industrie et du Numérique.

Il délivre les brevets, marques, dessins et modèles et donne accès à toute l'information sur la propriété industrielle et les entreprises.

Il participe activement à l'élaboration et à la mise en œuvre des politiques publiques dans le domaine de la propriété industrielle et de la lutte anti-contrefaçon.

Dr Leila Equinet
IP counselor 

Institut Pasteur United States

Dr Jean-Loup Romet-Lemonne
Senior Advisor Global Development 

Institute for Life Sciences Collaboration United States

At ILSC, we believe that collaboration and innovation are the best ways to tackle the world’s most pressing health challenges. As a result, we strive to encourage and enhance the development of innovative initiatives and collaborative approaches. To achieve our mission, we have formed strong partnerships with leading experts, academic institutions, organizations, and key stakeholders, including Yale UniversityIBMUNA-USACIMIT, and the Climate Remediation Foundation. Through our collaborations, we aim to make meaningful and measurable improvements in the global healthcare landscape.

Aaron Etra
, Secretary & Treasurer 

Integrative Center for Wellness United States

Provides psychiatric and wellness services to individuals seeking a healthy balance between mind and body. With an ever-increasing amount of medical research now linking brain chemistry with physical health, we strongly support a holistic approach to healthcare that integrates psychiatric and nutritional treatments and emphasizes whole-body wellness.

The founder of the Center is a psychiatrist with an extensive background in internal medicine. He has over twenty years of experience treating patients in the New York City area.

Ms Kimberly Macleod
CAO 

Integrative Center for Wellness United States

Dr. Ahmad’s clinical philosophy reflects the wisdom of the Greek physician Hippocrates: it is more important to know what person the disease has than what disease the person has.

“Our bodies are a unique function of both our genetics and our environment. I am committed to understanding each individual’s differences, getting to know the patient behind the illness, and providing the best treatment with therapy, medication and nutrition.”

Samoon Ahmad, MD

Dr Samoon Ahmad
Founder, Physician 

Intellitech France

Intellitech Robust Predictive Modeling of Complex Processes based on an Intelligent Analysis of Big / Smart Data Industry sectors Other: Predictive Me Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution

Our xtractis' robot incorporates the latest advances in Artificial Intelligence, especially Fuzzy Logic and Machine Learning. It analyses a multidimensional database and automatically discovers robust fuzzy rule-based Decision Support Systems which are able to predict with the most reliability the complex process under study.

Which problem are you solving ?

Robust Predictive Models for Epigenetics Personalized Medicine and Pharmacogenomics: Drug Discovery (efficiency, toxicity), Early Diagnosis, Companion Diagnostic, Virtual Screening, Selection of Best Target Patients, Disease Evolution, Survival Duration, Preventive Care, Environmental/Life-style/Diet/Therapeutic Recommendations, Side Effects & Adverse Events, Protein Homology, Reimbursement Rate of a Drug, Insurance Risk Scoring of a Patient

Target market segments

Pharmaceutical Industry / Personalized Medicine Diagnostics / Hospitals & Medical Centers / Private or Public Insurers

Key value proposition

Unique mathematical approach (fuzzy, possibilistic, inductive, automatic, holistic, non-linear, non-monotonic, without a priori) / Proprietary algorithms implemented in fully automated software with user-friendly MMI / Better predictive capacity (robustness) vs. prevailing world-class techniques / Handles weak signals and low quality data

Website:
www.xtractis.com
Prof. Zyed ZALILA
President and CEO